On 19thNovember’14, BrilliantPennyStocks.com initiated coverage on VDRM. The stock moved down by 8.61% till now since the coverage was initiated.
Viaderma Inc (OTCMKTS:VDRM)’s stock fell 6% to end the session at $0.0329. The stock has lost more than 20% in last five sessions and is trading much below its 52-week high of $0.61. The downtrend in stock cannot continue for long since the company is doing great with its lead product and talent acquisition.
Most recently, Viaderma announced the appointment of Dr. Andrew Berman as a Medical Director of its advisory board. Dr. Berman will contribute to the development and expansion of ViaDerma’s proprietary transdermal delivery system. He holds M.D., MPH and brings considerable experience of working in Beverly Hills area and greater California hospitals including Midway-Olympia Hospital. His clinical interests include diabetes mellitus and otolaryngology.
Viaderma started recruiting best of talents to its advisory board in fall. The Board is intended to provide strategic support and business development consultation.
TetraStem’s Innovative Technology
Viaderma Inc (OTCMKTS:VDRM)’s lead product TetraStem is a topical liquid, which has demonstrated success in healing diabetic wounds. TetraStem’s innovative transdermal delivery system could certainly help prevent amputations. According to the American Diabetes Association, approximately 73,000 diabetic patients required non-traumatic lower-limb amputations in 2010.
TetraStem, a tetracycline-based antibiotic, is found to be 99 percent effective against all bacteria in laboratory trials. It can kill bacteria chemically and physically because of proprietary transdermal delivery.
Dr. Christopher Otiko, CEO of Viaderma, said that TetraStem could help improve quality of life by reducing the need of amputations in patients suffering with diabetic wounds.
Hopes and Concerns
Dr. Simone McConnie, COO of the Barbados Diabetes Foundation, said that TetraStem could make a huge difference in reducing the number of amputations in Barbados. The drug TetraStem has been introduced in Barbados to serve about 230 patients that undergo amputations in Barbados every year.
However, a local pharmacist raised concern about how an antibiotic drug could prevent amputations, which are usually done for gangrene where the limb is rotting. He suggested to wait for more clinical evidences and research publications to see how an antibiotic drug could help address arterial and circulation issues.